Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VEGFA | P15692 | 2/20 | 0.32 |
| ▸ | EPAS1 | Q99814 | 2/20 | 0.32 |
| ▸ | PDE4A | P27815 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | RXRA | P19793 | 1/20 | 0.30 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.30 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.30 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16797109 | 0.84 | RXRA (0.31) | RXRA | |
| SCHEMBL29470879 | 0.77 | KDM1A (0.33) | RXRA | |
| SCHEMBL16035613 | 0.77 | KDM1A (0.33) | RXRA | |
| SCHEMBL16797206 | 0.77 | KMT2A (0.41) | EPAS1ALDH1A1 | |
| SCHEMBL30990174 | 0.75 | KMT2A (0.34) | VEGFAEPAS1PDE4AALDH1A1RXRA | |
| SCHEMBL22124670 | 0.72 | MEN1 (0.32) | — | |
| SCHEMBL16958146 | 0.71 | PDE4A (0.44) | PDE4AALDH1A1PDE4BPDE4CPDE4D | |
| SCHEMBL5546215 | 0.71 | MBOAT4 (0.33) | ALDH1A1 | |
| SCHEMBL18150337 | 0.71 | SLC6A2 (0.46) | PDE4AALDH1A1PDE4BPDE4CPDE4D | |
| SCHEMBL30640919 | 0.71 | PDE4A (0.44) | PDE4AALDH1A1PDE4BPDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3080123-B1 | IMIDAZOPYRIDINE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB Biopharma SRL (BE) | 2020-06-17 | — | — | EP | disclosed |
| US-9926313-B2 | Imidazopyridine derivatives as modulators of TNF activity | UCB BIOPHARMA SPRL (BE) | 2018-03-27 | — | — | US | disclosed |
| CN-105814046-B | Imidazopyridine derivatives as TNF active regulators | UCB生物制药私人有限公司 | 2018-01-30 | — | — | CN | disclosed |
| US-20160304513-A1 | Imidazopyridine Derivatives As Modulators of TNF Activity | UCB BIOPHARMA SPRL (BE) | 2016-10-20 | — | — | US | disclosed |
| EP-3080123-A1 | IMIDAZOPYRIDINE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB Biopharma SPRL (BE) | 2016-10-19 | — | — | EP | disclosed |
| CN-105814046-A | Imidazopyridine derivatives as modulators of TNF activity | UCB生物制药私人有限公司 | 2016-07-27 | — | — | CN | disclosed |
| WO-2015086509-A1 | IMIDAZOPYRIDINE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB BIOPHARMA SPRL (BE) | 2015-06-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160304513-A1 | Imidazopyridine Derivatives As Modulators of TNF Activity | TNF, TNFRSF1A, TNFRSF9 | VEGFA 1468/4885EPAS1 2034/4885PDE4A 62/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.